Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Plus a plant-derived COVID-19 vaccine moves into Phase II/III
Executive Summary
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.